OncoMatch

OncoMatch/Clinical Trials/NCT07085988

Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

Is NCT07085988 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for nasopharyngeal carcinoma (npc).

Phase 2RecruitingJiangxi Provincial Cancer HospitalNCT07085988Data as of May 2026

Nasopharyngeal carcinoma (NPC) is a malignant tumor that develops in the nasopharyngeal mucosal epithelium. Due to the disease itself and the impact of anti-tumor therapy, malnutrition has become a common clinical complication in patients with NPC, among which NPC patients receiving concurrent chemoradiotherapy are one of the groups with the highest incidence of malnutrition, and malnutrition seriously affects the prognosis of NPC patients. Nutritional management throughout the course has a positive impact on the prognosis and life management of NPC patients. As an immune-enhancing oral nutritional preparation, it is helpful to maintain the weight and immune function of patients with nasopharyngeal carcinoma during concurrent chemoradiotherapy, reduce the degree of treatment-related side effects during concurrent chemoradiotherapy for nasopharyngeal carcinoma, and delay the occurrence of acute side effects. The purpose of this study was to investigate the effect of rapid rapid rapid improvement of patients' immune status during concurrent chemoradiotherapy, and to further evaluate its impact on patients' weight, prognosis, treatment-related toxic side effects, and quality of life. In this study, 109 patients with nasopharyngeal carcinoma who received concurrent chemoradiotherapy in our hospital are planned to be included, and all patients in this group will be given oral tachyphin at a standard dose from the first day of radiotherapy. The nutritional immune status of the patient was assessed at different points during the treatment period.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Required: Stage II, III, IVA

Performance status

KPS OR ECOG 60–3

KPS score ≥ 60 or ECOG score ≤3

Lab requirements

Blood counts

serum hemoglobin ≥ 90 g/l, platelet ≥ 100×109/l, absolute neutrophil count ≥ 1.5×109/l

Kidney function

serum creatinine ≤1.25 times uln or creatinine clearance ≥60 ml/min

Liver function

serum bilirubin ≤ 1.5-fold uln, ast (sgot) and alt (sgpt) ≤ 2.5-fold uln, and alkaline phosphatase ≤ 5-fold uln

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify